Myrexis cancer news
Myrexis will restructure and reduced headcount by 57 (41%) to 81 and will focus resources on its pipeline of cancer candidates. The reductions primarily came from Myrexis' internal drug discovery group and include VP General Counsel Andrew Gibbs. Additionally, the biotech said it will close its research services business.
Myrexis' lead candidate Azixa verubulin, a small molecule microtubule destabilizing apoptosis-inducer, is in Phase IIb testing for glioblastoma multiforme (GBM). Myrexis has exclusive rights to Azixa, which has Orphan Drug designation in the U.S. for the indication, from EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT, Tarrytown, N.Y.). Myrexis' oncology pipeline also includes: MPC-3100, a fully-synthetic, non-geldanamycin small molecule inhibitor of heat shock protein 90 (Hsp90), which is in Phase I testing for refractory or relapsed cancer; and preclinical compounds MPC-9528, a small molecule inhibitor of nicotinamide phosphoribosyl transferase (NamPRT), and MPI-0485520, a I-kappa B kinase ( IKK)-epsilon and TANK-binding kinase 1 (TBK1) inhibitor. ...